Vishal N Rao1, Di Zhao2, Matthew A Allison3, Eliseo Guallar2, Kavita Sharma4, Michael H Criqui3, Mary Cushman5, Roger S Blumenthal4, Erin D Michos6. 1. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, Maryland; Division of Cardiology, Duke University School of Medicine, Durham, North Carolina. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Division of Preventive Medicine, University of California San Diego, La Jolla, California. 4. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, Maryland. 5. Division of Hematology, University of Vermont, Burlington, Vermont. 6. Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, Maryland; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. Electronic address: edonnell@jhmi.edu.
Abstract
OBJECTIVES: This study sought to compare various measures of adiposity with risk for incident hospitalized heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). BACKGROUND: Obesity is a risk factor for HF, particularly HFpEF. It is unknown which measures of adiposity, including anthropometrics and computed tomography (CT)-measured fat area, are most predictive of HF subtypes. METHODS: The authors studied 1,806 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) study without baseline cardiovascular disease who underwent anthropometrics (body mass index [BMI] and waist circumference) and an abdominal CT. Subcutaneous and visceral adipose tissue (VAT) were measured from a single CT slice at L2-L3. Cox hazard models were used to examine associations of adiposity with incident hospitalized HFpEF and HFrEF events. Fully adjusted models included demographics, HF risk factors, and N-terminal pro-B-type natriuretic peptide. RESULTS: Over a mean follow-up of 11 years, there were 34 HFpEF and 36 HFrEF events. The fully adjusted hazard ratio (95% confidence interval [CI]) per 1-SD higher of each anthropometric and CT-measured adiposity measures for incident HFpEF were as follows: BMI HR: 1.66; 95% CI: 1.12 to 2.45; waist circumference HR: 1.59; 95% CI: 1.05 to 2.40; and VAT HR: 2.24; 95% CI: 1.44 to 3.49. None of these adiposity measures were associated with HFrEF. Even among overweight/obese adults (BMI ≥25 kg/m2), assessment of VAT (per 1-SD) was strongly associated with HFpEF (HR: 2.78; 95% CI: 1.62 to 4.76). Subcutaneous adipose tissue was neither associated with HFpEF nor HFrEF. CONCLUSIONS: In a multiethnic cohort free of cardiovascular disease, CT-measured VAT was independently associated with incident hospitalized HFpEF but not HFrEF. Measuring visceral fat at the time of CT imaging for other indications may offer additional prognostication of HF risk. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
OBJECTIVES: This study sought to compare various measures of adiposity with risk for incident hospitalized heart failure (HF) with preserved ejection fraction (HFpEF) and reduced ejection fraction (HFrEF). BACKGROUND:Obesity is a risk factor for HF, particularly HFpEF. It is unknown which measures of adiposity, including anthropometrics and computed tomography (CT)-measured fat area, are most predictive of HF subtypes. METHODS: The authors studied 1,806 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) study without baseline cardiovascular disease who underwent anthropometrics (body mass index [BMI] and waist circumference) and an abdominal CT. Subcutaneous and visceral adipose tissue (VAT) were measured from a single CT slice at L2-L3. Cox hazard models were used to examine associations of adiposity with incident hospitalized HFpEF and HFrEF events. Fully adjusted models included demographics, HF risk factors, and N-terminal pro-B-type natriuretic peptide. RESULTS: Over a mean follow-up of 11 years, there were 34 HFpEF and 36 HFrEF events. The fully adjusted hazard ratio (95% confidence interval [CI]) per 1-SD higher of each anthropometric and CT-measured adiposity measures for incident HFpEF were as follows: BMI HR: 1.66; 95% CI: 1.12 to 2.45; waist circumference HR: 1.59; 95% CI: 1.05 to 2.40; and VAT HR: 2.24; 95% CI: 1.44 to 3.49. None of these adiposity measures were associated with HFrEF. Even among overweight/obese adults (BMI ≥25 kg/m2), assessment of VAT (per 1-SD) was strongly associated with HFpEF (HR: 2.78; 95% CI: 1.62 to 4.76). Subcutaneous adipose tissue was neither associated with HFpEF nor HFrEF. CONCLUSIONS: In a multiethnic cohort free of cardiovascular disease, CT-measured VAT was independently associated with incident hospitalized HFpEF but not HFrEF. Measuring visceral fat at the time of CT imaging for other indications may offer additional prognostication of HF risk. (Multi-Ethnic Study of Atherosclerosis [MESA]; NCT00005487).
Authors: Frank P Brouwers; Rudolf A de Boer; Pim van der Harst; Adriaan A Voors; Ron T Gansevoort; Stephan J Bakker; Hans L Hillege; Dirk J van Veldhuisen; Wiek H van Gilst Journal: Eur Heart J Date: 2013-03-06 Impact factor: 29.983
Authors: Evan D Muse; David I Feldman; Michael J Blaha; Zeina A Dardari; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir; Michael H Criqui; Mary Cushman; Robyn L McClelland; Matthew A Allison Journal: Atherosclerosis Date: 2014-12-23 Impact factor: 5.162
Authors: Peter Wohlfahrt; Margaret M Redfield; Francisco Lopez-Jimenez; Vojtech Melenovsky; Garvan C Kane; Richard J Rodeheffer; Barry A Borlaug Journal: JACC Heart Fail Date: 2014-09-03 Impact factor: 12.035
Authors: Bhavya Varma; Oluseye Ogunmoroti; Chiadi E Ndumele; Di Zhao; Moyses Szklo; Ty Sweeney; Matthew A Allison; Matthew J Budoff; Vinita Subramanya; Alain G Bertoni; Erin D Michos Journal: Diabet Epidemiol Manag Date: 2021-12-23
Authors: Kershaw V Patel; Matthew W Segar; Carl J Lavie; Nitin Kondamudi; Ian J Neeland; Jaime P Almandoz; Corby K Martin; Salvatore Carbone; Javed Butler; Tiffany M Powell-Wiley; Ambarish Pandey Journal: Circulation Date: 2021-12-03 Impact factor: 29.690
Authors: Ty Sweeney; Oluseye Ogunmoroti; Chiadi E Ndumele; Di Zhao; Bhavya Varma; Matthew A Allison; Matthew J Budoff; Oluwaseun E Fashanu; Apurva Sharma; Alain G Bertoni; Erin D Michos Journal: Atherosclerosis Date: 2021-11-05 Impact factor: 5.162
Authors: Sunyoung Jang; Oluseye Ogunmoroti; Chiadi E Ndumele; Di Zhao; Vishal N Rao; Oluwaseun E Fashanu; Martin Tibuakuu; James D Otvos; Eve-Marie Benson; Pamela Ouyang; Erin D Michos Journal: Circ Heart Fail Date: 2020-07-28 Impact factor: 8.790
Authors: Katlyn E Koepp; Masaru Obokata; Yogesh N V Reddy; Thomas P Olson; Barry A Borlaug Journal: JACC Heart Fail Date: 2020-07-08 Impact factor: 12.035
Authors: Kershaw V Patel; Judy L Bahnson; Sarah A Gaussoin; Karen C Johnson; Xavier Pi-Sunyer; Ursula White; KayLoni L Olson; Alain G Bertoni; Dalane W Kitzman; Jarett D Berry; Ambarish Pandey Journal: Circulation Date: 2020-11-09 Impact factor: 29.690
Authors: Shingo Takahara; Mourad Ferdaoussi; Nikola Srnic; Zaid H Maayah; Shubham Soni; Anna K Migglautsch; Rolf Breinbauer; Erin E Kershaw; Jason R B Dyck Journal: Am J Physiol Heart Circ Physiol Date: 2020-11-13 Impact factor: 4.733
Authors: Ambarish Pandey; Sanjiv J Shah; Javed Butler; Dean L Kellogg; Gregory D Lewis; Daniel E Forman; Robert J Mentz; Barry A Borlaug; Marc A Simon; Julio A Chirinos; Roger A Fielding; Elena Volpi; Anthony J A Molina; Mark J Haykowsky; Flora Sam; Bret H Goodpaster; Alain G Bertoni; Jamie N Justice; James P White; Jingzhone Ding; Scott L Hummel; Nathan K LeBrasseur; George E Taffet; Iraklis I Pipinos; Dalane Kitzman Journal: J Am Coll Cardiol Date: 2021-09-14 Impact factor: 27.203